Loading...
Loading...
OCS| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 16.5M |
| Gross Profit | -16.2M |
| Operating Expense | 6.3M |
| Operating I/L | -22.5M |
| Other Income/Expense | 1.7M |
| Interest Income | 0.7M |
| Pretax | -20.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -20.8M |
Oculis Holding AG is a clinical-stage biopharmaceutical company specializing in developing novel topical treatments for ophthalmic diseases. Their lead candidate, OCS-01, is a topical dexamethasone formulation in Phase 3 clinical trials for diabetic macular edema. OCS-02, a topical biologic candidate, is in Phase 2b clinical trials for dry eye disease, and OCS-05 is a neuroprotective agent for various neuro-ophthalmic disorders. The company generates revenue through the development and potential commercialization of these innovative ophthalmic treatments.
